Molecular Response (MRL) and Scripps Genomic Medicine Announce Joint Discovery/Development Agreement

Published: Jun 01, 2011

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today a joint discovery/development agreement with Scripps Genomic Medicine that will advance research in the areas of oncology and cardiovascular disease.

Back to news